New and experimental therapies for HCV. (Q37539700)

20 August 2017

1 reference

title

New and experimental therapies for HCV. (English)

1 reference

20 August 2017

Arema A Pereira

1

1 reference

PubMed ID

19575025

20 August 2017

Ira M Jacobson

series ordinal

2

1 reference

PubMed ID

19575025

20 August 2017

language of work or name

English

0 references

publication date

1 July 2009

1 reference

Nature Reviews Gastroenterology & Hepatology

20 August 2017

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

20 August 2017

6

1 reference

20 August 2017

7

1 reference

20 August 2017

403-411

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2009.92

20 August 2017

0 references

cites work

Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Epidemiology of hepatitis C: geographic differences and temporal trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Hepatitis C and liver transplantation: enhancing outcomes and should patients be retransplanted

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Viral heterogeneity of the hepatitis C virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Complete replication of hepatitis C virus in cell culture

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Cell entry of hepatitis C virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Unravelling hepatitis C virus replication from genome to function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Structural biology of hepatitis C virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Self-assembly of nucleocapsid-like particles from recombinant hepatitis C virus core protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Binding of hepatitis C virus to CD81

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

The Level of CD81 Cell Surface Expression Is a Key Determinant for Productive Entry of Hepatitis C Virus into Host Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Preclinical Evaluation of Two Neutralizing Human Monoclonal Antibodies against Hepatitis C Virus (HCV): a Potential Treatment To Prevent HCV Reinfection in Liver Transplant Patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Clinical evaluation (Phase I) of a human monoclonal antibody against hepatitis C virus: safety and antiviral activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Short-term cytotoxic effects and long-term instability of RNAi delivered using lentiviral vectors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

From structure to function: new insights into hepatitis C virus RNA replication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

NIM811, a Cyclophilin Inhibitor, Exhibits Potent In Vitro Activity against Hepatitis C Virus Alone or in Combination with Alpha Interferon

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Effects of interferon, ribavirin, and iminosugar derivatives on cells persistently infected with noncytopathic bovine viral diarrhea virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

In vitro production of Mallory bodies and intracellular hyaline bodies: the central role of sequestosome 1/p62.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

The tumor suppressor gene DLEC1 is frequently silenced by DNA methylation in hepatocellular carcinoma and induces G1 arrest in cell cycle.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Volume expanders for spontaneous bacterial peritonitis: Are we comparing oranges with oranges?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Activation of anti-hepatitis C virus responses via Toll-like receptor 7.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Analysis of a successful immune response against hepatitis C virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Endotoxemia contributes to the immune paralysis in patients with cirrhosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2009.92

Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19575025

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRGASTRO.2009.92

1 reference

20 August 2017

1 reference

PubMed ID

19575025